COST-EFFECTIVENESS ANALYSIS (CEA) BETWEEN ERLOTINIB AND GEFITINIB FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN THAILAND

被引：0
|
作者：
Prasongsook, Naiyarat [1 ]
Jaruhathai, Sureerat [1 ]
Maoleekulpairoj, Savitree [1 ]
Sooksriwong, Chaoncin [1 ]
机构：
[1] Mahidol Univ, Fac Pharm, Bangkok 10700, Thailand
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
TK1; Cost-effectiveness; gefitinib; erlotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1245 / S1246
页数：2
相关论文
共 50 条
  • [1] A COMPARATIVE CLINICAL AND COST-EFFECTIVENESS EVALUATION OF GEFITINIB AND ERLOTINIB IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
    Lopes, Gilberto D. L., Jr.
    Segel, Joel
    Tan, Daniel
    Do, Young
    Mok, Tony
    Finkelstein, Eric
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1306 - S1307
  • [2] Cost-effectiveness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand
    Limwattananon, Chulaporn
    Limwattananon, Supon
    Waleekhachonloet, Onanong
    Rattanachotphanit, Thananan
    LUNG CANCER, 2018, 120 : 91 - 97
  • [3] Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib
    Vasile, Enrico
    Tibaldi, Carmelo
    Chella, Antonio
    Falcone, Alfredo
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (08) : 912 - 914
  • [4] Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel
    Arrieta, Oscar
    Anaya, Pablo
    Morales-Oyarvide, Vicente
    Alejandra Ramirez-Tirado, Laura
    Polanco, Ana C.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2016, 17 (07) : 855 - 863
  • [5] EFFICACY OF ERLOTINIB AFTER THE FAILURE OF GEFITINIB IN PATIENTS WITH ADVANCED OR METASTASIS NON-SMALL CELL LUNG CANCER
    Wang Yan
    Li Junling
    Wang Ziping
    Guo Jihong
    Yu Shufei
    Hao Xuezhi
    Hu Xingsheng
    Wang Bin
    Zhang Xiangru
    Shi Yuankai
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1238 - S1239
  • [6] Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
    Shu, Yamin
    Zhang, Qilin
    He, Xucheng
    Chen, Li
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 8297 - 8306
  • [7] ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENT
    Goncalves, Ivone M.
    Monteiro, Regina
    Neves, Sofia
    Conde, Sara
    Campainha, Sergio
    Parente, Barbara
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1298 - S1298
  • [8] COST EFFECTIVENESS ANALYSIS BETWEEN GEFITINIB AND ERLOTINIB IN THE TREATMENT OF ADVANCED /METASTATIC NON SMALL CELL LUNG CANCER IN THAILAND BY PAYER'S PERSPECTIVE: SIX YEARS DATA FOLLOW UP
    Jaruhathai, Sureerat
    Maoleekoonpairoj, Savitree
    Chaichamnan, Pawarisa
    Sangviroon, Alisara
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S609 - S609
  • [9] EXPERIENCE OF USING ERLOTINIB FOR TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Kanazawa, Kenya
    Ishida, Takashi
    Suzuki, Aya
    Tachihara, Motoko
    Minemura, Hiroyuki
    Sekine, Satoko
    Oshima, Kengo
    Yokouchi, Hiroshi
    Watanabe, Kana
    Tanino, Yoshinori
    Munakata, Mitsuru
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1310 - S1310
  • [10] Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer A Real-World Cost-Effectiveness Analysis
    Cromwell, Ian
    van der Hoek, Kimberly
    Melosky, Barbara
    Peacock, Stuart
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (12) : 2097 - 2103
12345